Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126034492 | 12603449 | 2 | F | 20140102 | 20160802 | 20160728 | 20160812 | EXP | US-BAYER-2016-107654 | BAYER | 73.00 | YR | E | M | Y | 0.00000 | 20160812 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126034492 | 12603449 | 1 | SS | XARELTO | RIVAROXABAN | 1 | Oral | 15 MG, QD | 1710 | MG | Y | N | UNKNOWN | 0 | 15 | MG | FILM-COATED TABLET | QD | |
| 126034492 | 12603449 | 2 | PS | ACETYLSALICYLIC ACID({=100 mg) | ASPIRIN | 1 | Unknown | UNK | U | 999999 | TABLET | ||||||||
| 126034492 | 12603449 | 3 | SS | PLETAL | CILOSTAZOL | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126034492 | 12603449 | 1 | Thrombosis prophylaxis |
| 126034492 | 12603449 | 2 | Product used for unknown indication |
| 126034492 | 12603449 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126034492 | 12603449 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126034492 | 12603449 | Haemoptysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126034492 | 12603449 | 1 | 20130911 | 20140108 | 0 |